Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 71205-292

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 71205-292). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-292-30 (Rabe 30 Count)

Label for Rabeprazole Sodium 20 mg delayed-release tablets, prescription drug by Proficient Rx LP. The label states each tablet contains 20 mg Rabeprazole Sodium, with 30 tablets per package. The product is stored at 25°C and manufactured by Alkem Laboratories Limited, Mumbai, India. Tablets are described as yellow, round, biconvex, beveled, coated, with '20' imprinted in black on one side.*

FDA Label Image

Rabe-str (Rabe Str)

Chemical structure diagram of rabeprazole sodium, showing the arrangement of atoms and bonds within the molecule.*

FDA Label Image

Rabe-str2 (Rabe Str2)

A line graph showing mean heartburn scores over a 28-day study period for three groups: placebo (n=68), rabeprazole 10 mg (n=64), and rabeprazole 20 mg (n=67). The x-axis represents study days from -14 to 28, and the y-axis shows mean scores from 0 (none) to 4 (very severe). Scores decrease notably after day 0 for rabeprazole groups compared to placebo.*

FDA Label Image

Rabe-str3 (Rabe Str3)

A line graph comparing mean heartburn scores over a 28-day study period for Rabeprazole Sodium 20 mg delayed-release tablets versus placebo. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (None) to 4 (Very Severe). The graph shows a decrease in heartburn scores following treatment start at day 0.*

FDA Label Image

Rabe-str4 (Rabe Str4)

A line graph comparing mean heartburn scores over a 28-day study period between a placebo group and a Rabeprazole Sodium 20 mg group. The x-axis represents study days, ranging from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The Rabeprazole group consistently shows lower scores than the placebo group after day 0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.